High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma

Li,Bo; Zhu,Jie; Meng,Lei

doi:10.3892/mmr.2018.9716

High expression of ACTL8 is poor prognosis and accelerates cell progression in head and neck squamous cell carcinoma

Authors:
- Bo Li
- Jie Zhu
- Lei Meng
View Affiliations

Affiliations: Department of Neurosurgery, Jinan Central Hospital Affiliated to Shandong University, Jinan, Shandong 250013, P.R. China
Published online on: December 3, 2018 https://doi.org/10.3892/mmr.2018.9716
Pages: 877-884
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Actin‑like protein 8 (ACTL8) is a member of the cancer‑testis antigens (CTA) family, which is mainly localized in the cytoplasm and generally expressed in the testis. The association between ACTL8 and various types of cancer, including glioblastoma and breast cancer, has previously been demonstrated. However, whether ACTL8 is involved in the development of head and neck squamous cell carcinoma (HNSCC) remains unknown. In the present study, the expression of ACTL8 in patients with HNSCC was analyzed in The Cancer Genome Atlas (TCGA) dataset, clinical tissues and cell lines. Correlations between the expression levels of ACTL8 and HNSCC clinical outcomes were analyzed with the Kaplan‑Meier method and the Cox proportional hazards model. Cell Counting Kit‑8, plate colony formation and Transwell assays were used to assess the effects of ACTL8 interference on the proliferation, migration and invasion of HNSCC PCI‑13 cells. Reverse transcription‑quantitative polymerase chain reaction and western blotting were used to evaluate the expression levels of ACTL8 in PCI‑13 cells. Furthermore, alterations in the expression levels of key proteins in the phosphatidylinositol‑4,5‑bisphosphate 3‑kinase (PI3K)/RAC‑α protein kinase B (AKT) signaling pathway were determined by western blotting. Increased expression of ACTL8 in HNSCC was observed in TCGA dataset, cancerous tissue samples and HNSCC cell line. Cox regression analysis indicated that ACTL8 expression could be regarded as an independent prognostic factor for HNSCC, since increased expression of ACTL8 was associated with a poor prognosis. Knocking down ACTL8 markedly inhibited the proliferation, invasion and migration of PCI‑13 cells. Additionally, activation of the PI3K/AKT signaling pathway was suppressed by reduced expression levels of certain key proteins in this pathway. The present data indicate that ACTL8 serves a role in the progression and clinical prognosis of HNSCC. Therefore, ACTL8 may be a potential prognostic marker and novel therapeutic target for HNSCC.

View Figures

View References

1	Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pries R, Nitsch S and Wollenberg B: Role of cytokines in head and neck squamous cell carcinoma. Expert Rev Anticancer Ther. 6:1195–1203. 2006. View Article : Google Scholar : PubMed/NCBI
3	Stacy DR, Ely K, Massion PP, Yarbrough WG, Hallahan DE, Sekhar KR and Freeman ML: Increased expression of nuclear factor E2 p45-related factor 2 (NRF2) in head and neck squamous cell carcinomas. Head Neck. 28:813–818. 2006. View Article : Google Scholar : PubMed/NCBI
4	Scanlan MJ, Simpson AJ and Old LJ: The cancer/testis genes: Review, standardization and commentary. Cancer Immun. 4:12004.PubMed/NCBI
5	Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, Nuño MA, Richardson JE, Fan X, Ji J, Chu RM, et al: Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 62:125–135. 2013. View Article : Google Scholar : PubMed/NCBI
6	Atanackovic D, Blum I, Cao Y, Wenzel S, Bartels K, Faltz C, Hossfeld DK, Hegewisch-Becker S, Bokemeyer C and Leuwer R: Expression of cancer-testis antigens as possible targets for antigen-specific immunotherapy in head and neck squamous cell carcinoma. Cancer Biol Ther. 5:1218–1225. 2006. View Article : Google Scholar : PubMed/NCBI
7	Freitas M, Malheiros S, Stávale JN, Biassi TP, Zamunér FT, de Souza Begnami M, Soares FA and Vettore AL: Expression of cancer/testis antigens is correlated with improved survival in glioblastoma. Oncotarget. 4:636–646. 2013. View Article : Google Scholar : PubMed/NCBI
8	Yao J, Caballero OL, Yung WK, Weinstein JN, Riggins GJ, Strausberg RL and Zhao Q: Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. Cancer Immunol Res. 2:371–379. 2014. View Article : Google Scholar : PubMed/NCBI
9	Jin Y, Jin C, Wennerberg J, Mertens F and Höglund M: Cytogenetic and fluorescence in situ hybridization characterization of chromosome 1 rearrangements in head and neck carcinomas delineate a target region for deletions within 1p11-1p13. Cancer Res. 58:5859–5865. 1998.PubMed/NCBI
10	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
11	Giudice FS and Squarize CH: The determinants of head and neck cancer: Unmasking the PI3K pathway mutations. J Carcinog Mutagen. (Suppl 5):(pii): 0032013.PubMed/NCBI
12	Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa M, et al: miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget. 2:29–42. 2011. View Article : Google Scholar : PubMed/NCBI
13	De Castro G, Dos Anjos CH, Lalami Y and Awada A: Clinical trial design in advanced head and neck cancer: From past experiences to future perspectives. Clin Invest. 2:473–481. 2012. View Article : Google Scholar
14	Le Tourneau C, Faivre S and Siu LL: Molecular targeted herapy of head and neck cancer: Review and clinical development challenges. Eur J Cancer. 43:2457–2466. 2007. View Article : Google Scholar : PubMed/NCBI
15	Dhodapkar MV, Osman K, Teruya-Feldstein J, Filippa D, Hedvat CV, Iversen K, Kolb D, Geller MD, Hassoun H, Kewalramani T, et al: Expression of cancer/testis (CT) antigens MAGE-A1, MAGE-A3, MAGE-A4, CT-7 and NY-ESO-1 in malignant gammopathies is heterogeneous and correlates with site, stage and risk status of disease. Cancer Immun. 3:92003.PubMed/NCBI
16	Balafoutas D, Zur HA, Mayer S, Hirschfeld M, Jaeger M, Denschlag D, Gitsch G, Jungbluth A and Stickeler E: Cancer testis antigens and NY-BR-1 expression in primary breast cancer: Prognostic and therapeutic implications. BMC Cancer. 13:2712013. View Article : Google Scholar : PubMed/NCBI
17	Taylor M, Bolton LM, Johnson P, Elliott T and Murray N: Breast cancer is a promising target for vaccination using cancer-testis antigens known to elicit immune responses. Breast Cancer Res. 9:R462007. View Article : Google Scholar : PubMed/NCBI
18	Atanackovic D, Arfsten J, Cao Y, Gnjatic S, Schnieders F, Bartels K, Schilling G, Faltz C, Wolschke C, Dierlamm J, et al: Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation. Blood. 109:1103–1112. 2007. View Article : Google Scholar : PubMed/NCBI
19	Atanackovic D, Altorki NK, Cao Y, Ritter E, Ferrara CA, Ritter G, Hoffman EW, Bokemeyer C, Old LJ and Gnjatic S: Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on priming. Proc Natl Acad Sci USA. 105:1650–1655. 2008. View Article : Google Scholar : PubMed/NCBI
20	Fourcade J, Sun Z, Pagliano O, Chauvin JM, Sander C, Janjic B, Tarhini AA, Tawbi HA, Kirkwood JM, Moschos S, et al: PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. Cancer Res. 74:1045–1055. 2014. View Article : Google Scholar : PubMed/NCBI
21	Postow MA, Luke JJ, Bluth MJ, Ramaiya N, Panageas KS, Lawrence DP, Ibrahim N, Flaherty KT, Sullivan RJ, Ott PA, et al: Ipilimumab for patients with advanced mucosal melanoma. Oncologist. 18:726–732. 2013. View Article : Google Scholar : PubMed/NCBI
22	Britschgi A, Andraos R, Brinkhaus H, Klebba I, Romanet V, Müller U, Murakami M, Radimerski T and Bentires-Alj M: JAK2/STAT5 Inhibition circumvents resistance to PI3K/mTOR blockade: A rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell. 22:796–811. 2012. View Article : Google Scholar : PubMed/NCBI
23	Yang S, Ji Q, Chang B, Wang Y, Zhu Y, Li D, Huang C, Wang Y, Sun G, Zhang L, et al: STC2 promotes head and neck squamous cell carcinoma metastasis through modulating the PI3K/AKT/Snail signaling. Oncotarget. 8:5976–5991. 2017.PubMed/NCBI
24	Zheng W, Nagaraju G, Liu Z and Liu K: Functional roles of the phosphatidylinositol 3-kinases (PI3Ks) signaling in the mammalian ovary. Mol Cell Endocrinol. 356:24–30. 2012. View Article : Google Scholar : PubMed/NCBI
25	Okkenhaug K and Vanhaesebroeck B: PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 3:317–330. 2003. View Article : Google Scholar : PubMed/NCBI
26	Yuan TL and Cantley LC: PI3K pathway alterations in cancer: Variations on a theme. Oncogene. 27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
27	Zhao XF and Gartenhaus RB: Phospho-p70S6K and cdc2/cdk1 as therapeutic targets for diffuse large B-cell lymphoma. Expert Opin Ther Targets. 13:1085–1093. 2009. View Article : Google Scholar : PubMed/NCBI
28	Wang F, Qiu Y, Zhang HM, Hanson P, Ye X, Zhao G, Xie R, Tong L and Yang D: Heat shock protein 70 promotes coxsackievirus B3 translation initiation and elongation via Akt-mTORC1 pathway depending on activation of p70S6K and Cdc2. Cell Microbiol. 2017. View Article : Google Scholar :